>

Genmab Stock Analysis

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:3em;padding-top: 40px;;'>GMA</div>
GMAB -- Denmark Stock  

DKK 1,380  80.50  5.51%

Is it time to opt in on Genmab AS? Genmab AS Stock analysis can help investors discover the best opportunities and time the market in virtually any economy. Find the stocks trading at a discount of their intrinsic value will give you an edge in creating a market-bitting portfolio. The small decline in market price for the last few months may raise some interest from investors. The Stock closed today at a share price of 1374.0 on very low momentum in trading volume. The company executives did not add much value to Genmab AS investors in March. However, diversifying your holdings with Genmab AS or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 3.35. The above-average volatility is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Genmab AS partners. Please check Risk vs Return Analysis.
View Stock Analysis For
Refresh
The Genmab AS Stock analysis interface makes it easy to digest most current publicly released information about Genmab AS as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. Genmab stock analysis module also helps to analyze Genmab AS price relationship with some important fundamental indicators such as market cap and management efficiency.

Genmab Stock Analysis Notes

The company recorded earning per share (EPS) of 34.03. Genmab AS had not issued any dividends in recent years. Genmab AS, a biotechnology company, creates and develops antibody therapeutics for the treatment of cancer primarily in Denmark. Genmab AS was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab AS is traded on Copenhagen Stock Exchange in Denmark. To learn more about null call Jan Winkel at 45 70 20 27 28 or check out http://www.genmab.com.

Genmab AS Investment Alerts

Genmab AS generates negative expected return over the last 30 days
Genmab AS has high historical volatility and very poor performance

Market Capitalization

The company currently falls under 'Large-Cap' category with current market capitalization of 87.95 B.

Profitablity

The company has Profit Margin (PM) of 40.37 % which can be a sign that it executes well on its competitive strategies and has a good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 49.16 % which suggests for every 100 dollars of sales it generated a net operating income of 0.49.

Management Efficiency

Genmab AS has return on total asset (ROA) of 13.97 % which means that it generated profit of $13.97 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 19.64 % meaning that it generated $19.64 on every $100 dollars invested by stockholders.

Institutional Stock Holders for Genmab AS

Technical Drivers

As of the 7th of April Genmab AS retains Market Risk Adjusted Performance of 1.32 and Risk Adjusted Performance of (0.09). Genmab AS technical analysis makes it possible for you to employ historical prices and volume momentum with intention to determine a pattern that calculates the direction of the corporation future prices. Simply put, you can use this information to find out if the corporation will indeed mirror its model of historical price patterns or the prices will eventually revert. We found nineteen technical drivers for Genmab AS, which can be compared to its competitors. Please check out Genmab AS Standard Deviation, Information Ratio, Treynor Ratio, as well as the relationship between Variance and Jensen Alpha to decide if Genmab AS is priced fairly providing market reflects its last-minute price of 1379.5 per share.

Genmab AS Price Movement Analysis

The output start index for this execution was thirty-nine with a total number of output elements of twenty-two. Genmab AS Triple Exponential Moving Average indicator shows smoothing effect of Genmab AS price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average. View also all equity analysis or get more info about triple exponential moving average overlap studies indicator.

Genmab AS Technical and Predictive Indicators

Genmab AS Forecast Models

Did you try this?

Run Equity Forecasting Now

   

Equity Forecasting

Use basic forecasting models to generate price predictions and determine price momentum
All  Next Launch Module
Please check Risk vs Return Analysis. Please also try Companies Directory module to evaluate performance of over 100,000 stocks, funds, and etfs against different fundamentals.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page